SEC Form 10-K filed by Barinthus Biotherapeutics plc
$BRNS
Biotechnology: Pharmaceutical Preparations
Health Care
Unavailable
Unavailable
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
4 - Barinthus Biotherapeutics plc. (0001828185) (Issuer)
4 - Barinthus Biotherapeutics plc. (0001828185) (Issuer)
4 - Barinthus Biotherapeutics plc. (0001828185) (Issuer)
8-K/A - Barinthus Biotherapeutics plc. (0001828185) (Filer)
10-Q - Barinthus Biotherapeutics plc. (0001828185) (Filer)
8-K - Barinthus Biotherapeutics plc. (0001828185) (Filer)
The final cohort of the single ascending dose (SAD) part of the Phase 1 AVALON trial initiated, with the SAD data readout expected early in the fourth quarter of 2025;The multiple ascending dose (MAD) part of the AVALON trial initiated; Available resources and cash runway guidance into 2027 remains unchanged. GERMANTOWN, Md., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Barinthus Biotherapeutics plc (NASDAQ:BRNS) ("Barinthus Bio," or the "Company"), an immunology and inflammation ("I&I") company focused on developing therapies that promote immune tolerance with curative potential, today announced its financial results for the quarter ended June 30, 2025, and provided an overview of the Company's c
Highly differentiated immunotherapy for celiac disease (VTP-1000) in the clinic, with Phase 1 single ascending dose readout from AVALON expected in the third quarter of 2025;Initiation of VTP-1000 multiple ascending dose expected in the second half of 2025; Encouraging results from HBV003 and IM-PROVE II presented at EASL, supporting ongoing partnering efforts; Available resources expected to provide a cash runway into 2027. OXFORD, United Kingdom and GERMANTOWN, Md., May 07, 2025 (GLOBE NEWSWIRE) -- Barinthus Biotherapeutics plc (NASDAQ:BRNS) ("Barinthus Bio," or the "Company"), an immunology and inflammation ("I&I") company focused on developing therapies that promote immune tolerance
Strategic transformation ongoing, positioning the Company as a focused leader in immunology and inflammatory diseasesHighly differentiated, potentially curative immunotherapy for celiac disease (VTP-1000) in the clinic, with first data expected in third quarter of 2025Proprietary SNAP-TI platform promoting antigen-specific immune tolerance is anticipated to drive multiple future pipeline and partnership opportunities Strategic prioritization of resources expected to provide a cash runway into 2027 OXFORD, United Kingdom and GERMANTOWN, Md., March 20, 2025 (GLOBE NEWSWIRE) -- Barinthus Biotherapeutics plc (NASDAQ:BRNS) ("Barinthus Bio," or the "Company"), an immunology and inflammation (I&
OXFORD, United Kingdom and GERMANTOWN, Md., Nov. 25, 2024 (GLOBE NEWSWIRE) -- Barinthus Biotherapeutics plc (NASDAQ:BRNS) ("Barinthus Bio"), today announced the promotion of Geoffrey Lynn, M.D., Ph.D. to Chief Scientific Officer (CSO), effective as of December 1, 2024. Dr. Lynn succeeds Nadège Pelletier, Ph.D. who decided to pursue alternative opportunities closer to home after having served as Barinthus Bio's CSO since early 2023. Barinthus Bio is a clinical-stage biopharmaceutical company developing novel immunotherapeutic candidates that guide T cells to control disease. "Dr. Pelletier's strong vision and leadership have resulted in a robust preclinical pipeline of promising leads for
OXFORD, United Kingdom, May 01, 2024 (GLOBE NEWSWIRE) -- Barinthus Biotherapeutics plc (NASDAQ:BRNS), formerly Vaccitech plc, a clinical-stage biopharmaceutical company developing novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer, today announced the appointment of Leon Hooftman, M.D., as Chief Medical Officer (CMO). "We are happy to welcome Dr. Hooftman to Barinthus Bio as our Chief Medical Officer. With his experience spearheading clinical studies from early development through late-stage trials, he is a valuable addition to the Barinthus Bio team during a critical time in our growth," said Chi
The final cohort of the single ascending dose (SAD) part of the Phase 1 AVALON trial initiated, with the SAD data readout expected early in the fourth quarter of 2025;The multiple ascending dose (MAD) part of the AVALON trial initiated; Available resources and cash runway guidance into 2027 remains unchanged. GERMANTOWN, Md., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Barinthus Biotherapeutics plc (NASDAQ:BRNS) ("Barinthus Bio," or the "Company"), an immunology and inflammation ("I&I") company focused on developing therapies that promote immune tolerance with curative potential, today announced its financial results for the quarter ended June 30, 2025, and provided an overview of the Company's c
Highly differentiated immunotherapy for celiac disease (VTP-1000) in the clinic, with Phase 1 single ascending dose readout from AVALON expected in the third quarter of 2025;Initiation of VTP-1000 multiple ascending dose expected in the second half of 2025; Encouraging results from HBV003 and IM-PROVE II presented at EASL, supporting ongoing partnering efforts; Available resources expected to provide a cash runway into 2027. OXFORD, United Kingdom and GERMANTOWN, Md., May 07, 2025 (GLOBE NEWSWIRE) -- Barinthus Biotherapeutics plc (NASDAQ:BRNS) ("Barinthus Bio," or the "Company"), an immunology and inflammation ("I&I") company focused on developing therapies that promote immune tolerance
Strategic transformation ongoing, positioning the Company as a focused leader in immunology and inflammatory diseasesHighly differentiated, potentially curative immunotherapy for celiac disease (VTP-1000) in the clinic, with first data expected in third quarter of 2025Proprietary SNAP-TI platform promoting antigen-specific immune tolerance is anticipated to drive multiple future pipeline and partnership opportunities Strategic prioritization of resources expected to provide a cash runway into 2027 OXFORD, United Kingdom and GERMANTOWN, Md., March 20, 2025 (GLOBE NEWSWIRE) -- Barinthus Biotherapeutics plc (NASDAQ:BRNS) ("Barinthus Bio," or the "Company"), an immunology and inflammation (I&
SC 13G/A - Barinthus Biotherapeutics plc. (0001828185) (Subject)
SC 13G - Barinthus Biotherapeutics plc. (0001828185) (Subject)